24/7 Market News Snapshot 03 June, 2025 – Traws Pharma, Inc. Common Stock (NASDAQ:TRAW)

June 3, 2025

DENVER, Colo., 03 June, 2025 (www.247marketnews.com) – (NASDAQ:TRAW) are discussed in this article.
Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases, is experiencing a significant surge in market interest, with its stock price jumping 143.94% to $3.464 in pre-market trading. This notable increase reflects heightened investor confidence, contributing to a trading volume of over 11.22 million shares. The momentum surrounding TRAW indicates a potentially lucrative opportunity for investors looking to engage with a company poised for growth.

In addition to its market performance, Traws Pharma recently announced groundbreaking clinical efficacy data for rigosertib, an oncology asset now targeting cutaneous squamous cell carcinoma (SCC) in patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). The results of this pivotal study, published in the British Journal of Dermatology, reveal an extraordinary overall response rate of 80%, with half of the evaluable patients achieving complete responses. Dr. Victor Moyo, Chief Medical Officer of Oncology at Traws Pharma, emphasized the significance of these findings, highlighting rigosertib’s potential as a treatment for a patient population with an urgent medical need and no approved therapies currently available.

Interim CEO Iain Dukes articulated the company’s commitment to advancing rigosertib, recognizing the devastating impact of RDEB-associated SCC. He noted the importance of the collaboration among patients, investigators, and sponsors in bringing these results to fruition. Traws Pharma is now actively seeking partners for the development and commercialization of rigosertib, aiming to expedite progress towards approval and provide relief to those affected by this challenging disease.

As Traws Pharma continues to pursue innovative solutions in health care, its recent advancements underscore the company’s dedication to addressing critical health challenges and fulfilling unmet medical needs.

Related news for (TRAW)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.